Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compared With Placebo
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This is a placebo-controlled, 3-period crossover study to assess the efficacy and safety of
two single doses of an intranasal anti-histamine GSK1004723 compared with placebo in an
allergen challenge chamber in male subjects with seasonal allergic